Johnson & Johnson, known for the production of medical devices, pharmaceutical and consumer packaged goods, announced in January that the company had created a single-dose vaccine against the coronavirus.
According to The New York Times, a single dose of the vaccine had an efficacy rate of up to 72%. Though many think it could be a more efficient alternative to the Pfizer and Moderna vaccines because of its single-dose nature, researchers have limited knowledge of how well the vaccine will work when released, due to the Phase 3 results having yet to be published.
Johnson & Johnson began work on the vaccine in January 2020, always intending to create a single-dose vaccine. In August, Johnson & Johnson entered into an agreement with the federal government to be paid $1 billion for 100 million doses. In October, the European Union entered into a deal for 200 million doses.
There was immense pressure on the company to create a vaccine that would work, while also requiring only a single dose. However, it hit a speedbump: on Oct. 12, the company paused their first Phase 3 trial in order to investigate adverse effects in a volunteer. The volunteer’s illness was not serious, however. After a short investigation, it was determined not to be a result of the vaccine.
The trials have continued, and they are currently behind schedule; however, results are expected to be released this month. The vaccine has been proven to be 100% effective in preventing hospitalizations and death from COVID-19, though it has been less effective than those of Pfizer and Moderna in preventing moderate to severe coronavirus.